Live Feeds
● LIVE Updated 1h ago · 21 sources tracked

Kodiak skyrockets on positive study data for 2 eye drugs

Kodiak Sciences shares rose between 120% and 178% on September 28 after its Phase 3 DAYBREAK trial met primary endpoints for two eye-disease candidates. Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501) demonstrated statistical equivalence to aflibercept, sold as Eylea, in treating treatment-naive patients with wet age-related macular degeneration. Zenkuda achieved an average vision improvement of 7.2 letters compared to 7.6 for Eylea. The company now plans to seek regulatory approval for Zenkuda this year, adding more than $3 billion to its market value.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (21)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Zenkuda and tabirafusp alfa tedromer met primary endpoints in the Phase 3 DAYBREAK trial for wet age-related macular degeneration.
  • ✓ Both experimental drugs matched Eylea on vision improvement at one year.
  • ✓ Zenkuda showed an average vision improvement of 7.2 letters compared to 7.6 letters for Eylea.
  • ✓ Kodiak Sciences shares increased sharply on September 28, with reports of gains ranging from 120% to 178%.
🛡️ Source Corroboration: 21 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Kodiak Sciences announced Phase 3 DAYBREAK trial results showing two candidates matched Eylea in vision improvement.

Live updates

  1. Kodiak Sciences stock surges on positive Phase 3 wet AMD trial data

    Kodiak Sciences shares rose between 120% and 178% on September 28 after its Phase 3 DAYBREAK trial met primary endpoints for two eye-disease candidates. Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501) demonstrated statistical equivalence to aflibercept, sold as Eylea, in treating treatment-naive patients with wet age-related macular degeneration. Zenkuda achieved an average vision improvement of 7.2 letters compared to 7.6 for Eylea. The company now plans to seek regulatory approval for Zenkuda this year, adding more than $3 billion to its market value.

    Why it matters

    The results resurrect a drug Kodiak had shelved in 2023 following a cataract safety signal. These candidates compete directly with Regeneron's Eylea in the retinal disease market. The company currently generates no revenue and faces significant cash-burn risks.

    What is confirmed

    • Zenkuda and tabirafusp alfa tedromer met primary endpoints in the Phase 3 DAYBREAK trial for wet age-related macular degeneration.
    • Both experimental drugs matched Eylea on vision improvement at one year.
    • Zenkuda showed an average vision improvement of 7.2 letters compared to 7.6 letters for Eylea.
    • Kodiak Sciences shares increased sharply on September 28, with reports of gains ranging from 120% to 178%.
    • The company intends to seek regulatory approval for Zenkuda this year.

    Still unconfirmed

    • A share offering is likely for the cash-burning biotech.
    • The positive findings added more than $3 billion to the company's market value.

    What to watch next

    • FDA filing for Zenkuda
    • Official BLA submission date
    • Company announcement regarding financing or share offerings
    Sources used for this update (27)
    1. biopharmadive.com — Kodiak skyrockets on positive study data for 2 eye drugs
    2. Forbes — Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
    3. Fierce Biotech — Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
    4. Yahoo Finance — Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
    5. Investor's Business Daily — Why This Regeneron Eye Rival Just Catapulted More Than 120%
    6. FirstWord — Kodiak surges on Phase III victory for Eylea rival in wet AMD
    7. finance.yahoo.com — Why Kodiak Sciences Skyrocketed Today
    8. www.fiercebiotech.com — Kodiak's stock doubles as resurrected eye disease drug ...
    9. www.biospace.com — Kodiak Sciences’ stock soars 166% after 2 assets ... - BioSpace
    10. finance.yahoo.com — Kodiak skyrockets on positive study data for 2 eye drugs
    11. www.talk.bio — Kodiak stock surges after two eye-drug candidates match Eylea ...
    12. www.marketbeat.com — KOD News Today | Why did Kodiak Sciences stock go up today? $KOD
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community